Mar 07, 2023 / 02:50PM GMT
Wade Walke -
Well, I'd like to thank TD Cowen for inviting Ionis to present today at their conference. I am Wade Walke, I'm the Head of Investor Relations at Ionis Pharmaceuticals. I would like to remind everyone that I will be making forward-looking statements, and I would encourage you to take a look at the risk factors that we've outlined in our SEC filings to get a better idea of the context. The Ionis of today is not the same company that I joined over 10 years ago.
There's many key differences. Back then, Ionis was really focused on building an R&D engine, which still has today, one of the most astounding R&D engines I've ever seen. And -- but back then, they were focused on building a genetic medicines company that was focused on building a new platform technology for drug discovery, focused on antisense. And they did a remarkable job in that endeavor. I would just point you to SPINRAZA as an example of a blockbuster drug that came out of that effort. But back then, we were really focused on a partnering strategy that would help us to develop that technology and our pipeline.
Ionis Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers